You are here: Industry Insights > NICE

News List

NICE publishes final guidance backing Teva's Ajovy for migraine pharmatimes
June 05, 2020
The National Institute for Health and Care Excellence (NICE) has now published final guidelines endorsing the NHS use of Teva’s Ajovy (fremanezumab) to prevent migraine.
NICE u-turn backs Roche's Tecentriq for small-cell lung cancer pharmatimes
May 29, 2020
A combination of Roche's Tecentriq (atezolizumab), carboplatin and etoposide has now been recommended as an NHS-funded option for untreated extensive-stage small-cell lung cancer (ES-SCLC), following an earlier rejection by cost regulators.
NICE issues final guidance on NHS use of Bayer's Vitrakvi pharmatimes
May 28, 2020
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending NHS use of Bayer's Vitrakvi (larotrectinib) for a variety of cancers.
NICE u-turn backs Roche's Tecentriq for triple negative breast cancer pharmatimes
May 27, 2020
NICE is now backing NHS use of Tecentriq (atezolizumab) with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer, following an “improved offer” from drugmaker Roche.
New COVID-19 guidelines for CKD and interstitial lung disease pharmatimes
May 19, 2020
The National Institute for Health and Care Excellence has published two new rapid COVID-19 guidelines for chronic kidney disease (CKD) and interstitial lung disease.
NICE backs use of Roche's Gazyvaro with bendustamine pharmatimes
May 14, 2020
Patients with follicular lymphoma will now get NHS-funded treatment with Roche's Gazyvaro (binutuzumab)/bendamustine in England and Wales after cost regulators published guidelines backing its use in this setting.
NICE final guidance backs Pfizer's Lorviqua pharmatimes
May 13, 2020
The National Institute for Health and Care Excellence (NICE) has published guidance recommending the use of Pfizer's Lorviqua (lorlatinib) for a certain form of lung cancer on the NHS.
UK’s NICE recommends Roche breast cancer drug Kadcyla pharmaceutical-technology
May 12, 2020
The National Institute for Health and Care Excellence (NICE) in the UK has recommended the use of Roche’s Kadcyla (trastuzumab emtansine) to treat certain patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
NICE joins international COVID-19 pandemic response pharmatimes
May 07, 2020
The National Institute for Health and Care Excellence (NICE) says it is supporting a growing number of international collaborations striving to share knowledge and identify new treatments in response to the COVID-19 pandemic.
NICE publishes latest set of COVID-19 guidelines pharmatimes
May 05, 2020
The National Institute for Health and Care Excellence (NICE) has published its latest set of rapid coronavirus guidelines, for the care of immunocompromised people under 17 years old and adults hospitalised with pneumonia.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page